The effects of recombinant human interleukin-3 (IL-3) and recombinant human granulocyte colony-stimulating factor (G-CSF) on the growth of myeloid progenitor cells (CFU-C) in semisolid agar culture were studied in two patients with Kostmann-type congenital neutropenia. CFU-C growth in bone marrow cells from patients was significantly reduced in response to various concentrations of either IL-3 or G-CSF alone, compared with that from normal subjects. There was no inhibitory effect of bone marrow cells from patients on normal CFU-C formation supported by IL-3 or G-CSF. However, the simultaneous stimulation with IL-3 and G-CSF induced the increase of CFU-C formation in patients with congenital neutropenia. Furthermore, CFU-C growth in both patients was supported when bone marrow cells were preincubated with IL-3 in liquid culture followed by the stimulation with G-CSF in semisolid agar ONGENITAL NEUTROPENIAS are a heterogenous C group of disorders. Kostmann-type neutropenia is a unique subgroup of these diseases and is characterized by the early onset of severe and recurrent infections, absence of neutrophils in the peripheral blood, and a bone marrow picture of maturation arrest of myeloid progenitor cells at the promyelocyte-myelocyte stage.'-3 There have been several reports on in vitro granulopoiesis by semisolid colony formation and liquid-suspension culture, and the results from these reports have been ~ariable.~." However, in a majority of patients the proliferative and maturational potentials of myeloid progenitor cells in bone marrow have been considered normal in the presence of various colony-stimulating factors (CSFs), suggesting a deficiency in growth factor production as a possible cause of this Recently, CSFs that control the proliferation and the differentiation of hematopoietic progenitor cells have been purified, molecularly cloned, and expressed as recombinant proteins."-'3 These factors are classified according to the types of hematopoietic progenitor cells with which they interact. It is generally accepted that recombinant human interleukin-3 (IL-3) induces the proliferation of stem cells and committed progenitors of multiple cell lineages, and that recombinant human granulocyte CSF (G-CSF) stimulates the terminal differentiation of granulocyte precursors.14- '6 In this report, we study the effects of IL-3 and G-CSF on the proliferation of myeloid progenitor cells in patients with Kostmann-type congenital neutropenia. The results demonstrate that myeloid progenitor cells in patients proliferate in response to combined and sequential stimulation with IL-3 and G-CSF, although those fail to react with either IL-3 or G-CSF alone.
MATERIALS AND METHODS
Two patients with Kostmann-type congenital neutropenia were studied. Patient 1 was a 3-year-old boy who contracted otitis media at the age of 6 months. At the age of 11 months he had a high fever of 2 weeks' duration due to a liver abscess that was treated by surgical drainage. At that time, the complete blood cell count showed a total white blood cell (WBC) count of 7.6 x 109/L, with no
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culture. In contrast, that was not supported by the preincubation with G-CSF and the subsequent stimulation with IL-3. This evidence suggests that the hematopoietic progenitor cells in patients with congenital neutropenia have the potential for developing CFU-C in the combined stimulation with IL-3 and G-CSF, and that this growth may be dependent on the priming of IL-3 followed by the stimulation with G-CSF. The level of mature neutrophils in peripheral blood was not fully restored to normal levels by the daily administration of G-CSF in doses of 100 to 200 pg/m2 of body surface area for 20 to 25 days in both patients. These observations raise the possibility that the combination of IL-3 and G-CSF might have a potential role for the increase of neutrophil counts in patients with congenital neutropenia. 0 1990 by The American Society of Hematology.
neutrophils. Red blood cell (RBC) and platelet counts were normal. Bone marrow aspiration showed the normal cellularity with a maturation arrest at the promyelocyte stage. After this event he was started on prophylactic sulfamethoxazole-trimethoprim and rifampin. However, he continued to have recurrent skin abscesses and chronic gingivitis. During the 22 months of follow-up, total WBC count ranged from 4.7 to 9.5 x 109/L, with an absolute neutrophil count (ANC) of 0 to 0.102 x 109/L. Patient 2 was a 2-year-old boy who presented at the age of 2 months with pneumonia. His WBC count was 5 x 109/L with an ANC of 0.05 x 109/L. RBC and platelet counts were normal. Bone marrow aspiration showed the normal cellularity with a deficiency of neutrophil precursors beyond the myelocyte stage. Since the age of 3 months, he has been maintained on daily administration of sulfamethoxazole-trimethoprim. Despite the prophylaxis, he had repeated hospitalizations due to respiratory tract infections and bacteremias. During the 24 months of follow-up, total WBC count ranged from 4 to 10.5 x 109/L, with an ANC of 0 to 0.25 x 109/L. IL-3, which was prepared by expressing in Escherichia coli followed by further purification, was the generous gift of Genetics Institute, Cambridge, MA. G-CSF that was produced with E coli, according to recombinant DNA techniques, was kindly supplied by Kirin-Amgen Co, Tokyo, Japan, and Sankyo Co Ltd, Tokyo, Japan.
Bone marrow cells. All bone marrow samples were obtained after informed consent of patients and/or their guardians. Normal bone marrow cells for this study were obtained from hematologically 2144 KOBAYASHI ET AL normal pediatric patients ranging in age from 9 months to 5 years who underwent the procedure for diagnostic purposes. Bone marrow aspirates from both patients and normal subjects for all experiments were performed during apparent infection-free periods.
The aspirated bone marrow cells were diluted with Iscove's modified Dulbecco's medium (IMDM; GIBCO, Grand Island, NY), layered over Ficoll-sodium metrizoate (1.077 g/mL, Nyegaard & Co, Norway), and centrifuged for 30 minutes at 400 x g. Interface cells were washed three times, resuspended in IMDM with 10% heat-inactivated fetal bovine serum (FBS; Hazleton, Lenexa, KS) at a concentration of lo6 cells/mL and incubated in plastic dishes at 37OC over 3 hours to remove the adherent cells.
Myeloid progenitor cell (CFU-C) assay was performed using a semisolid agar method originally described by Pike and Robinson" with modification in 35-mm plastic dishes (Falcon, Oxnard, CA).8 Bone marrow nonadherent cells (5 x lo4 or 1 x lo5 cells) were plated in 1 mL IMDM containing 0.3% Bactoagar (Difco Lab, Detroit, MI), 20% FBS, 1% bovine serum albumin (BSA; Sigma Chemical Co, St Louis, MO), 5 x mol/L 2-mercaptoethanol (Nacalai Tesque, Kyoto, Japan), and various concentrations of IL-3 and/or G-CSF. The cultures were incubated at 37°C in a humidified atmosphere with 5% CO, for 7 to 10 days. Colonies were defined as clones of more than 40 cells. CFU-C counts represent the mean of duplicate or triplicate cultures. To determine the cellular composition of the resulting colonies, histochemical analyses using esterase double-staining methods in the agar gel as a whole plate preparation were performed and CFU-C were grouped into three classes, such as granulocyte-colony (G-colony), macrophage-colony (M-colony), and granulocyte/macrophage-colony (GM-colony), according to the previously described method.'.'' In some experiments, 0.9% methylcellulose (Nacalai Tesque) cultures were performed and morphologic examinations of cells picked up in colony were determined by the Cytospin (Shandon Southern, Elliott, IL) preparations with Wright's stain and/or esterase double stain.
For liquid culture experiments, bone marrow nonadherent cells prepared as described above (1 x 106/mL) were initially incubated in tissue culture flask in 5 mL IMDM plus 20% FBS with either IL-3 or G-CSF for up to 7 days. As for control, cells were incubated without any CSFs. The cultures were generally maintained by change of medium partially on the third or fourth day. After washing the cells completely, subsequent semisolid agar culture was performed in the presence of IL-3 or G-CSF for 7 days. CFU-C counts and cellular composition of the colonies on day 7 were determined as described above.
The patients received a sequential 10-to 14-day course of G-CSF in either daily 1-hour intravenous infusion or subcutaneous injections. The initial dose was 100 pg/m2 of body surface area per day. If there was no obvious response, the daily dose increased to 200 pg/m2 of body surface area for a subsequent 10 to 14 days. The responses were evaluated at that time.
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RESULTS
Responsiveness of myeloid progenitor cells to IL-3 or G-CSF alone.
The CFU-C formation stimulated by various concentrations of IL-3 or G-CSF in both normal subjects and patients with congenital neutropenia is presented in Fig  1 (IL-3) and Fig 2 (G-CSF) , respectively. In normal bone marrow cells, CFU-C growth in response to IL-3 and G-CSF was dose-dependent, and maximal CFU-C growth was elicited by the concentration of 100 U/mL of IL-3 and 50 ng/mL of G-CSF, respectively. In contrast to normal subjects, CFU-C from two patients with congenital neutropenia was markedly decreased in any concentrations of IL-3 and G-CSF. As shown in Tables 1 and 2 , most colonies formed by G-CSF from normal subjects and patients were positive for chloracetate esterase and negative for nonspecific esterase, consistent with the colonies being granulocytic in type. On the other hand, those supported by IL-3 consisted of three different types, identified as G-, GM-, and M-colonies.
Effect of bone marrow cells on CFU-C formation supported by IL-3 or G-CSF. To study the presence of inhibitory activity from patient bone marrow cells, we used the double-layer agar method. As shown in Table 3 , there was no inhibition of CFU-C formation from normal bone marrow cells in the presence of IL-3 or G-CSF when the bone marrow cells from patients were plated in the under layer. Alternatively, CFU-C formation supported by IL-3 was increased by the addition of the bone marrow cells in the under layer. There was no difference between normal subjects and the patients in the enhancement of CFU-C growth in the presence of IL-3. These results imply that the decrease of CFU-C formation stimulated by IL-3 or G-CSF in patients with congenital neutropenia is not due to the production of diffusible inhibitors by patients' bone marrow cells.
Responsiveness of myeloid progenitor cells to the combination of IL-3 and G-CSF. We and others have previously shown that CFU-C are present in normal numbers in a majority of congenital neutropenias.d'O It seems likely that the discrepancy of CFU-C formation between our present observations, as shown in Figs 1 and 2 and the results from prior reports, is due to the difference of CSFs. As has been reported, there are different or overlapping effects between the synthetic CSFs, such as IL-3 and G-CSF, and they frequently display synergistic or additive effects in supporting hematopoietic progenitor cell colony formation in serumcontaining ~u l t u r e . '~.~~ In normal subjects, increased CFU-C formation was found by the simultaneous addition of both IL-3 and G-CSF, as shown in Table 4 . This effect was notably observed when a low concentration of IL-3 was used. The effect of the combined stimulation with IL-3 and G-CSF on CFU-C formation in patients with congenital neutropenia is also shown in Table 4 . Although IL-3 or G-CSF alone was insufficient for CFU-C formation, G-colony formation was markedly induced by stimulation with the combination of factors in both patients. However, there was a difference between the responses observed with the two patients' samples: in patient 1 the frequency of CFU-C obtained was only one fourth of that from the sample of patient 2.
In some experiments, colonies formed by these factors from either patient were picked from methylcellulose culture and analyzed for their cellular composition. These colonies contained myeloid cells at various stages of maturation, from myeloblasts to segmented neutrophils (data not shown). This result is consistent with our previous report on suspension cultures of patient bone marrow cells.8 These observations suggest that bone marrow cells from patients with Kostmanntype congenital neutropenia are capable of normal proliferation and differentiation to mature myeloid cells in response to appropriate CSFs.
Responsiveness of myeloid progenitor cells in patients to sequential stimulation with IL-3 and G-CSF. To study further the proliferative effect of the combination of IL-3 and G-CSF in patients, we performed secondary cultures in semisolid medium after primary liquid cultures in the presence of IL-3 or G-CSF. The results from both patients are presented in Fig 3. When bone marrow nonadherent cells were preincubated with IL-3 for up to 7 days, there was no CFU-C formation in the absence of subsequent stimulation with any CSFs (data not shown). However, the induction of CFU-C formation was observed with the subsequent stimulation with G-CSF but not with IL-3. There was no difference between the concentrations of subsequent G-CSF. Maximal CFU-C formation was seen at 4 or 5 days' preincubation with IL-3 in this condition (Fig 3A) . Most of the colonies formed by the primary stimulation with IL-3 for 4 days and the subsequent stimulation with G-CSF were granulocytic (Table 5) . These results were comparable with those from simultaneous addition of IL-3 and G-CSF in patient 2. In patient 1, the sequential stimulation was more conducive to CFU-C formation than the simultaneous stimulation with both factors. In contrast, preincubation in G-CSF led to little CFU-C formation in cultures subsequently supported by either IL-3 or G-CSF (Fig 3B) .
Effect of the administration of G-CSF on absolute neutrophil counts of peripheral blood in patients. We administered recombinant human G-CSF in doses of 100 to 200 pg/m2 of body surface area to both patients when they were apparently infection-free. As shown in Table 6 , the absolute neutrophil counts in peripheral blood in both patients were slightly increased by the administration of G-CSF. However, Bone marrow nonadherent cells (1 x lo5 cells) were plated in 1 mL IMDM containing 0.5% Bactc-agar, 20% FBS. and 1% BSA in the under layer.
The composition of the upper layer and the experimental conditions were similar to those described in Materials and Methods. The representative results from two different experiments in each patient are shown.
'Number of C F U C per 1 x lo5 bone marrow nonadherent cells from normal subjects.
the dose of G-CSF used in this study design did not lead to an increase in normal levels of mature neutrophils.
DISCUSSION
The research on recombinant hematopoietic CSFs has recently been intensified in the re-examination and therapeutic management of congenital and acquired bone marrow dis- tioned medium, and human omentum-conditioned medium!.' ' IL-3 is capable of supporting the growth of multilineage erythroid, myeloid, and megakaryocytic colonies, as well as that of mast cells.14.15*'9-22 G-CSF, on the other hand, is generally believed to be a lineage-specific hematopoietic factor that directly supports the proliferation of neutrophil c~l o n i e s . '~~'~~'~ However, there are somewhat overlapping effects between IL-3 and G-CSF, and they frequently display synergistic or additive effects in supporting hematopoietic progenitor cell colony formation in serum-containing ~ondition."-~~.~' The ability of the simultaneous stimulation of IL-3 and G-CSF to restore the granulocyte-colony formation in patients was remarkable. The relationship between IL-3-and G-CSF-mediated growth was further studied after preculture of bone marrow cells in patients with congenital neutropenia. Granulocyte colonies were supported when the bone marrow cells were preincubated in suspension culture in the presence of IL-3 with subsequent culture in semisolid medium in the presence of G-CSF, but not when the order of exposure to the factors was reversed. These observations provide the possibilities that granulocyte colony formation in patients requires both stimulation of IL-3 and G-CSF, and that this may be dependent on the priming of IL-3 followed by the stimulation with G-CSF. These data from patients are in accordance with those that IL-3 has been capable of maintaining the number of CFU-C in liquid culture of normal human bone marrow cells, but G-CSF has not.32'34 A similar effect of IL-3 has also been found in the proliferation of erythroid progenitors, suggesting that IL-3 either stimulates self-renewal of both erythroid burstforming unit and CFU-C, or alternatively, drives erythroid and myeloid commitment from antecedent pluripotent ~e I l s .~~.~~ Although there was a difference in the frequency of CFU-C formation supported by the simultaneous addition of IL-3 and G-CSF between patients ( Table 4) , similar numbers of CFU-C were induced by the sequential stimulation with these factors ( Table 5 ) . At present, the basis for this phenomenon is not known. However, these differences may in part be due to the cellular variety related to the heterogeneity of this disorder"' or to the cellular responsiveness to G-CSF in the liquid culture after the stimulation with IL-3. It has been reported that there should be a potentiating effect on CFU-C development supported by the combined stimulation with IL-3 and G-CSF.I9 Sieff et aI2' found the specific induction of granulocyte colonies by the combined stimulation with IL-3 and G-CSF, suggesting that distinct subsets of granulocytic precursors exist that respond to IL-3, G-CSF, or both factors combined.
It remains unclear why CFU-C formation stimulated by either IL-3 or G-CSF alone is reduced in patients with congenital neutropenia. One interpretation is that the inability of IL-3 or G-CSF alone to induce CFU-C may be caused by a decrease in the frequency of cells responsive to each CSF. As for G-CSF, enriched populations of normal human promyelocytes and myelocytes have demonstrated specific labeling with '251-G-CSF and clonal proliferation when stimulated with G-CSF.37. 38 The proportion of promyelocytes and myelocytes or chloracetate esterase-positive cells in light-density adherence depleted marrow cells from both patients was clearly smaller than that from normal subjects; patient 1 was 0.5% to 1.3% and patient 2 was 1.2% to 2.8%, respectively (normal control, 13% to 27%). However, the progenitor cells that respond to IL-3 in the bone marrow are still not well-defined in serum-supplemented culture. In serum-free culture, Sonoda et a134 suggested that the primary targets of IL-3 are multipotent progenitors at the early stages of development.
Another explanation is that CFU-C growth from patients is more dependent on exogenously added CSFs than that from normal subjects because of possible underlying disturbances in the responsiveness to IL-3 or G-CSF. In our culture condition, CFU-C development may be affected by the potential factors in the serum and/or from accessory cells in the bone marrow. Wright et a13' suggested these possibilities from the data of mathematical models of the regulation of myelopoiesis in response to granulocyte-macrophage CSF in patients with childhood onset cyclic neutropenia. With highly purified marrow progenitors, Bot et a139 demonstrated that IL-3, although it did not stimulate granulocyte colony formation by itself, regulated the survival and proliferative rate of granulocytic progenitors. Furthermore, multi-CSF activity of IL-3 for CFU-G, CFU-GM, and CFU-M has been dependent on the availability of accessory cells that are present in our condition^.^' The increase of CFU-C formation in the presence of IL-3 was observed when the bone marrow cells from patients and normal subjects were plated in the under layer. This observation suggests that the bone marrow cells in patients may be capable of supporting the increase of CFU-C formation by IL-3.
Therefore, further examinations with more highly enriched hematopoietic progenitor cells and with defined, serum-depleted culture conditions should be necessary to clarify the growth factor requirements for the myeloid progenitors in patients with congenital neutropenia.
Recently, clinical trials of G-CSF to patients with a variety of different types of neutropenias have been startBonilla et a126 reported the G-CSF could lead to an increase of functional neutrophils in five patients with congenital agranulocytosis. However, the pattern of hematopoietic response differed from that previously reported after administration of growth factor to normal subjects, patients with myelodysplasia, or immunosuppressed patients. The effective dose of G-CSF varied among five patients, and some patients required high-dose administration of G-CSF to increase peripheral blood neutrophils. Weston et aI2' ed.24-29 reported the rise of neutrophil counts and therapeutic advance by G-CSF during the infectious period in patients with congenital neutropenia. On the other hand, the level of mature neutrophils in peripheral blood was not fully restored to normal levels in our patients by the administration of daily doses of G-CSF. Thus, the effect of G-CSF on the induction of mature neutrophils would not be expected to be uniform because of the heterogeneity of this disorder in which both the in vitro responsiveness of myeloid progenitor cells and the in vivo efficacy of G-CSF have already been reported to be ~a r i a b l e .~-"~~~ In view of our in vitro results, increases of mature neutrophils in patients with congenital neutropenia might best be obtained using a combination of the terminal differentiating factor G-CSF with exogenous or endogenous factors for early hematopoietic progenitor cell proliferation. Finally, further in vitro and in vivo analyses of more cases with congenital neutropenia using recombinant hematopoietic CSFs could define the pathogenesis and indicate a more suitable therapeutic approach to this disorder.
